| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Accounts payable | NaN | 1,653 | NaN | NaN |
| Accounts payable, related party | NaN | 0 | NaN | 0 |
| Loss on disposal of property and equipment | NaN | 0 | 0 | 0 |
| Amortization of right-of-use assets | NaN | NaN | 100 | 194 |
| Operating lease payments | NaN | NaN | 116 | 229 |
| Net loss for the period | -7,634 | -7,759 | -5,123 | -12,586 |
| Stock-based compensation | 129 | 42 | 44 | 391 |
| Change in fair value of warrants | NaN | 0 | NaN | NaN |
| Depreciation of property and equipment | 2 | 4 | 11 | 7 |
| Noncash operating lease expense | 104 | 396 | NaN | NaN |
| Interest on lease liabilities | 3 | 5 | 8 | 21 |
| Interest on loan payable to related party | 433 | 347 | 220 | 276 |
| Unrealized gain on short-term investment | 0 | NaN | NaN | NaN |
| Prepaid expenses | -364 | 196 | 156 | -396 |
| Other assets | 1,172 | 1,122 | 366 | 1,470 |
| Related party payable | NaN | NaN | 0 | NaN |
| Change in operating lease liability | -116 | -462 | NaN | NaN |
| Accounts payable | 701 | NaN | -1,423 | 1,621 |
| Accrued liabilities | 1,147 | 1,398 | -610 | 2,641 |
| Cash used in operating activities | -5,841 | -5,841 | -7,411 | -8,738 |
| Proceeds from disposal of property and equipment | NaN | 0 | 0 | 0 |
| Purchase of property and equipment | NaN | 0 | NaN | NaN |
| Cash provided by investing activities | 0 | 0 | 0 | 0 |
| Repayment of loan with related party | NaN | 0 | 0 | 100 |
| Issuance of common shares and warrants-November Two Thousand And Twenty Four Public Offering | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock-Committed Equity Facility | NaN | NaN | 0 | 0 |
| Issuance of common shares-June2024Registered Direct Offering | NaN | 0 | NaN | NaN |
| Issuance of common shares and warrants-Registered Direct Offering | NaN | NaN | 0 | 0 |
| Proceeds from warrant exercise-June Two Thousand And Twenty Four Pre Funded Warrant | NaN | 0 | NaN | NaN |
| Issuance of common shares and warrants-January Two Thousand And Twenty Four Public Offering | NaN | 0 | 0 | 0 |
| Issuance of common shares and warrants-Hanmi Private Placement | NaN | 0 | 0 | 0 |
| Issuance of common shares-Two Thousand Twenty Three Committed Equity Facility | NaN | 0 | NaN | NaN |
| Issuance of common shares-The2022Atm Offering | NaN | 0 | 0 | 0 |
| Proceeds from loan payable with related party | 5,850 | 8,300 | 7,750 | 2,600 |
| Issuance of common shares-The2025ATMOffering | 0 | 0 | 0 | 828 |
| Issuance of common shares-Employee Stock Purchase Plan | 0 | 0 | 0 | 1 |
| Cash provided by financing activities | 5,850 | 8,300 | 7,750 | 3,329 |
| Effect of exchange rate fluctuations on cash | 0 | NaN | NaN | NaN |
| Increase (decrease) in cash and restricted cash | 9 | 2,459 | 339 | -5,409 |
| Cash and restricted cash, beginning of period | 4,096 | 1,637 | 6,707 | NaN |
| Cash and restricted cash, end of period | 4,105 | 4,096 | 1,637 | NaN |
Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc. (APTOF)